多替阿巴拉米片上市时间

On January 22, 2018, GlaxoSmithKline (GSK) announced that its single-pill combination preparation (Triumeq) based on the new generation integrase inhibitor dolutegravir (DTG) for the treatment of HIV was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

Dolutegravir is a once-daily three-in-one drug developed by ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer. The drug is based on the treatment plan of the integrase inhibitor Tivicay (Dolutegravir) and also contains two nucleoside reverse transcriptase inhibitors, Abacavir and Lamivudine. It was approved by the FDA on August 27, 2014.

Dolutegra abalami tablets have strong competitiveness in the market: on the one hand, it combines several anti-HIV drugs with different mechanisms to achieve the effect of joint treatment; on the other hand, it is convenient to take, which greatly increases the patient's compliance with taking the drug, makes it easier to be accepted by the patient, and reduces the impact of the patient's inability to take the dose on time.

Precisely because of its excellent medicinal efficacy, dolutea abalami tablets entered the ranks of "blockbuster" drugs one year after its launch. Sales in 2015 reached US$949 million, and in 2016 they reached £1.735 billion (equivalent to approximately US$2.251 billion), ranking third among all anti-HIV drugs. In the first three quarters of 2017, the global sales of dolutea palamid tablets reached US$2.386 billion, a year-on-year increase of 70.8% (sales in the first three quarters of 2016 were 13.97), surpassing last year's HIV drug leader Truvada (US$2.337 billion in the first three quarters of 2017), and only less than US$300 million behind Genvoya, which is about to become the new leader in anti-HIV drugs in 2017.

It is conceivable that a new round of storm will surely be set off in the anti-AIDS market.